PS
RVNC

Principal Securities’s Revance Therapeutics, Inc. RVNC Stock Holding History

Principal Securities’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-509
Closed -$4.47K – 3402
2023
Q4 		$4.47K Buy
+509
New +$4.17K ﹤0.01% 2567

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Principal Securities's RVNC Position: Q1 2024 in Review

Principal Securities sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 509 shares — an estimated $4.47K sold.

Principal Securities first reported a position in RVNC in Q4 2023 and held it in 1 quarter. The position peaked at $4.47K in Q4 2023. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

  • Principal Securities reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
  • Principal Securities sold 509 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $4.47K.
  • Principal Securities first reported a position in Revance Therapeutics, Inc. in Q4 2023 and held it in 1 quarter.
  • Principal Securities's Revance Therapeutics, Inc. position peaked at $4.47K in Q4 2023.
  • 188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Principal Securities's 13F filing for Q1 2024, filed 10 May 2024.